IO Biotech Bilan de santé

Santé financière contrôle des critères 4/6

IO Biotech possède un total de capitaux propres de $72.6M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $89.9M et de $17.4M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$80.19m
Fonds propres	US$72.57m
Total du passif	US$17.38m
Total des actifs	US$89.95m

Mises à jour récentes de la santé financière

Recent updates

We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Jun 12

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Feb 10

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Jun 15

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Jan 20

IO Biotech names new CFO

Oct 13

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Sep 27

IO Biotech GAAP EPS of -$0.64

Aug 11

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Jun 14

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Feb 25

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de IOBT ( $86.2M ) dépassent ses passifs à court terme ( $16.1M ).

Passif à long terme: Les actifs à court terme de IOBT ( $86.2M ) dépassent ses passifs à long terme ( $1.3M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: IOBT est sans dette.

Réduire la dette: IOBT n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: IOBT dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: IOBT dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 36.3 % chaque année

IO Biotech Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Recent updates

IO Biotech, Inc. Announces Data from the NSCLC Cohort in the Phase 2 Basket Trial of IO102-IO103

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-Line Treatment of Advanced Head and Neck Cancer

Price target decreased by 13% to US$8.50

IO Biotech, Inc. Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

New major risk - Financial position

New minor risk - Share price stability

We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors

IO Biotech, Inc., Annual General Meeting, Jun 06, 2024

New minor risk - Market cap size

IO Biotech Announces Marjan Shamsaei as Senior Vice President

IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103

IO Biotech, Inc. Appoints Faiçal Miyara as Chief Business Officer

IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting

New major risk - Revenue and earnings growth

New minor risk - Market cap size

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

High number of new directors

IO Biotech Appoints Helen Collins, Md, to Its Board of Directors

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

New minor risk - Share price stability

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Price target decreased by 15% to US$9.67

IO Biotech, Inc. Appoints Heidi Hunter to Its Board of Directors

IO Biotech, Inc. announced that it expects to receive $75.057935 million in funding from a group of investors

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial At University of California Davis Comprehensive Cancer Center

IO Biotech, Inc. Announces Executive Changes

New minor risk - Share price stability

IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

IO Biotech, Inc. Appoints Christine Richter as Senior Vice President, Commercial and Program Lead

Chief Financial Officer recently bought US$58k worth of stock

IO Biotech Appoints Devin Smith as General Counsel and Chief Compliance Officer

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Price target decreased to US$17.50

IO Biotech, Inc. Announces Appointment of Amy Sullivan as Chief Financial Officer

IO Biotech names new CFO

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech GAAP EPS of -$0.64

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma

IO Biotech, Inc. Announces Executive Changes

High number of new directors

High number of new directors

IO Biotech, Inc. Announces its Two Directors Not Stand for Re-Election

IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting

IO Biotech, Inc. Announces Appointment of David V. Smith to Board of Directors

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines